By looking at the electrical activity of tumor cells, rather than the neurons that innervate them, investigators at Baylor College of Medicine have added both basic and translational insights to the emerging field of cancer neuroscience. In their studies, which were published in Cancer Cell on Sept. 5, 2024, the researchers identified the cell of origin for IDH-mutated gliomas.
Norroy Bioscience Co. Ltd. has prepared drug conjugates comprising a radionuclide linked to a ligand targeting glutamate carboxypeptidase II (NAALADase; NAAG peptidase, FOLH1; PSMA) through a linker for use as positron-emission tomography (PET) imaging agents.
Work at Dice Alpha Inc. has led to the discovery of new interleukin-17A (IL-17A) production inhibitors. They are reported to be potentially useful for the treatment of psoriasis, radiographic axial spondyloarthritis (ankylosing spondylitis), hidradenitis suppurativa, spondyloarthritis, psoriatic and rheumatoid arthritis.
Regeneron Pharmaceuticals Inc. has patented new 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17-β-HSD-13) inhibitors reported to be useful for the treatment of liver diseases.
Recent Ideaya Biosciences Inc. patents describe new poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
ML-218 is an orally active, selective, and potent T-type calcium channel (Cav3.1, Cav3.2 and Cav3.3) inhibitor. Previous research has shown that ML-218 penetrates the blood-brain barrier and exerts protective effects against haloperidol-induced catalepsy, peripheral neuropathy and Parkinson’s disease.
It has been previously demonstrated that the activation of spleen tyrosine kinase (SYK) contributes to processes that are central to the pathogenesis of neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).
TC Biopharm (Holdings) plc has announced plans to begin proof-of-concept preclinical studies for its lead therapeutic, TCB-008, for the treatment of mpox.
Multiple sulfatase deficiency (MSD) is a rare lysosomal storage disorder caused by pathogenic variants in the sulfatase modifying factor 1 gene (SUMF1). Researchers from the University of Pennsylvania described the efficacy of hematopoietic stem cell transplantation (HSCT) with ex vivo SUMF1 lentiviral gene therapy (SUMF1-GT) in a mouse model of MSD.
RSS
